 HOUSTON--BUSINESS WIRE--Kiromic BioPharma the Company NASDAQ: KRBP, a pre-clinical stage biotechnology company using its proprietary DIAMOND artificial intelligence A.I. platform to improve drug discovery and development with a therapeutic focus on immune-oncology, today announced its financial results for the third quarter ended September 30, 2020, and provided an update on its corporate developments. Kiromic BioPharma achieved important scientific and operational milestones duri 